The Cooper Companies with ticker code (COO) have now 13 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 560 and 280 calculating the average target price we see 353.92. With the stocks previous close at 345.17 this would imply there is a potential upside of 2.5%. The 50 day MA is 311.42 and the 200 day moving average is 321.69. The company has a market capitalisation of $16,990m. You can visit the company’s website by visiting: https://www.coopercos.com
The potential market cap would be $17,421m based on the market concensus.
The Cooper Companies, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women’s health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies was founded in 1958 and is headquartered in San Ramon, California.
